- Previous Close
31.60 - Open
31.48 - Bid 31.00 x --
- Ask 31.21 x --
- Day's Range
30.86 - 31.85 - 52 Week Range
21.17 - 36.42 - Volume
89,794 - Avg. Volume
45,006 - Market Cap (intraday)
1.119T - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
88.69 - EPS (TTM)
0.35 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield 0.19 (0.62%)
- Ex-Dividend Date Nov 15, 2024
- 1y Target Est
--
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com43,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent News: LLY.NE
View More
Related Videos: LLY.NE
Performance Overview: LLY.NE
Trailing total returns as of 2024-10-31, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LLY.NE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LLY.NE
View MoreValuation Measures
Market Cap
1.10T
Enterprise Value
1.13T
Trailing P/E
88.16
Forward P/E
36.10
PEG Ratio (5yr expected)
0.77
Price/Sales (ttm)
18.10
Price/Book (mrq)
54.54
Enterprise Value/Revenue
19.95
Enterprise Value/EBITDA
65.15
Financial Highlights
Profitability and Income Statement
Profit Margin
20.48%
Return on Assets (ttm)
13.95%
Return on Equity (ttm)
65.32%
Revenue (ttm)
40.86B
Net Income Avi to Common (ttm)
8.37B
Diluted EPS (ttm)
0.35
Balance Sheet and Cash Flow
Total Cash (mrq)
3.52B
Total Debt/Equity (mrq)
218.08%
Levered Free Cash Flow (ttm)
-1.31B